Todd C. Zion

grad student

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Alleva DG, Delpero AR, Sathiyaseelan T, et al. (2024) An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes. Frontiers in Immunology. 15: 1367514
Alleva DG, Feitsma EA, Janssen YF, et al. (2024) Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine. Npj Vaccines. 9: 40
Feitsma EA, Janssen YF, Boersma HH, et al. (2023) A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. Vaccine
Hulsebosch SE, Pires J, Bannasch MJ, et al. (2022) Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs. Journal of Veterinary Internal Medicine
Janssen YF, Feitsma EA, Boersma HH, et al. (2022) Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine. 40: 1253-1260
Alleva DG, Delpero AR, Scully MM, et al. (2021) Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine
Gilor C, Hulsebosch SE, Pires J, et al. (2021) An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats. Journal of Veterinary Internal Medicine